Key result
Atorvastatin does not alter glucose tolerance in normal weight PCOS patients with dyslipidemia.
Why the study?
Polycystic ovary syndrome is associated with disturbances in carbohydrate and lipid metabolism, and the effects of statins on glucose tolerance in PCOS patients are unclear.
Does atorvastatin 20 mg daily affect glucose tolerance in normal weight patients with PCOS and dyslipidemia?
Does atorvastatin 20 mg daily affect glucose tolerance in normal weight patients with PCOS and dyslipidemia?
p-value: p=0.59 for fasting glucose, 0.54 for 2-hour OGTT
Three months of atorvastatin 20 mg daily improved lipid profiles without adversely affecting glucose homeostasis in normal-weight women with PCOS and dyslipidemia.
Supports statin use for dyslipidemia in this PCOS case without glucose effects; leaves open confirmation in controlled trials.
Background and Aims. Polycystic ovary syndrome (PCOS) is associated with disturbances in carbohydrate and lipid metabolism. Statins appear to have beneficial effects in PCOS, although some meta-analyzes showed an increased risk of developing diabetes mellitus. The aim of this study was to evaluate the effect of treatment with 20 mg of atorvastatin daily for three months on glucose tolerance in a group of 8 normal weight patients with PCOS and dyslipidemia.Material andMethods. We evaluated 8 patients aged between 29 and 40 years, with normal weight, diagnosed with PCOS and dyslipidemia. The carbohydrate metabolism was assessed by oral glucose tolerance test (OGTT) before and after 3 months of therapy with 20 mg of atorvastatin daily.Results. Treatment with atorvastatin resulted in a statistically significant reduction in total cholesterol (p = 0.001), LDL cholesterol (p = 0.001), triglycerides (p = 0.01) and statistically significant increase in HDL cholesterol (p = 0.003). Fasting plasma glucose (p = 0.59) and the 2-hour OGTT glycemia (p = 0.54) were not significantly changed. Total testosterone decreased significantly ( p= 0.04).Conclusions. At baseline, all patients included in our study showed unaffected carbohydrate metabolism. Even after 3 months of therapy with atorvastatin 20 mg daily no changes in glucose homeostasis were noted.
No takes yet. Share an insight, caveat, or question.
Memu et al. (2013) studied Polycystic ovary syndrome and dyslipidemia (n=8). Atorvastatin vs. Baseline (before treatment) was evaluated on Glucose tolerance (fasting plasma glucose and 2-hour OGTT glycemia) (p=0.59 for fasting glucose, 0.54 for 2-hour OGTT). Atorvastatin 20 mg daily for 3 months did not significantly change fasting plasma glucose (p=0.59) or 2-hour OGTT glycemia (p=0.54) in normal weight patients with PCOS and dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: